Daxor Co. (NASDAQ:DXR) Short Interest Down 8.3% in January

Daxor Co. (NASDAQ:DXR) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 12,100 shares, a decline of 8.3% from the January 15th total of 13,200 shares. Based on an average daily volume of 16,500 shares, the short-interest ratio is presently 0.7 days. Approximately 0.6% of the company’s shares are short sold.

Daxor Price Performance

DXR stock traded up $0.05 during trading on Tuesday, reaching $7.23. The company had a trading volume of 1,158 shares, compared to its average volume of 5,662. Daxor has a 52 week low of $6.55 and a 52 week high of $10.00. The business has a 50 day moving average of $7.92 and a 200 day moving average of $8.61.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC increased its position in Daxor Co. (NASDAQ:DXR) by 34.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.